Cellares and TScan to assess automated manufacturing of TSC-101 therapy
Cellares and TScan Therapeutics have entered a deal to assess automated manufacturing for TScan’s TSC-101 therapy in AML and MDS patients.
Read the full article on the original site.
Read Full Article